BD HorizonTM BV480 Biosimilar Anti-Human CD20

Description

Flow cytometric analysis of Human CD20 Obinutuzumab Biosimilar expression on Human peripheral blood leukocytes. Human whole blood was stained with BD OptiBuild BV480 Human IgG1 N297A , kappa Isotype Control Cat. No. 756244; Left Plot or BD Horizon BV480 Biosimilar Anti-Human CD20 Obinutuzumab Biosimilar antibody Cat. No. 570971/571042; Right Plot . The erythrocytes were lysed with BD FACS Lysing Solution Cat. No. 349202 . The bivariate pseudocolor density plot showing the correlated expression of CD20 Obinutuzumab Biosimilar or Ig Isotype control staining versus side light-scatter SSC-A signals was derived from gated events with the forward and side light-scatter characteristics of intact leukocyte populations. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo Software. Flow cytometric analysis of Human CD20 Obinutuzumab Biosimilar expression on Human peripheral blood lymphocytes. Human whole blood was stained with PE Mouse Anti-Human CD19 antibody Cat. No. 555413 and with either BD OptiBuild BV480 Human IgG1 N297A , kappa Isotype Control Cat. No. 756244; Left Plot or BD Horizon BV480 Biosimilar Anti-Human CD20 Obinutuzumab Biosimilar antibody Cat. No. 570971/571042; Right Plot . The erythrocytes were lysed with BD FACS Lysing Solution Cat. No. 349202 . The bivariate pseudocolor density plot showing the correlated expression of CD20 Obinutuzumab Biosimilar or Ig Isotype control staining versus CD19 was derived from gated events with the forward and side light-scatter characteristics of intact lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo Software. Flow cytometric analysis of Human CD20 Obinutuzumab Biosimilar expression on Human peripheral blood leukocytes. Human whole blood was stained with BD OptiBuild BV480 Human IgG1 N297A , kappa Isotype Control Cat. No. 756244; Left Plot or BD Horizon BV480 Biosimilar Anti-Human CD20 Obinutuzumab Biosimilar antibody Cat. No. 570971/571042; Right Plot . The erythrocytes were lysed with BD FACS Lysing Solution Cat. No. 349202 . The bivariate pseudocolor density plot showing the correlated expression of CD20 Obinutuzumab Biosimilar or Ig Isotype control staining versus side light-scatter SSC-A signals was derived from gated events with the forward and side light-scatter characteristics of intact leukocyte populations. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo Software. Show More Flow cytometric analysis of Human CD20 Obinutuzumab Biosimilar expression on Human peripheral blood lymphocytes. Human whole blood was stained with PE Mouse Anti-Human CD19 antibody Cat. No. 555413 and with either BD OptiBuild BV480 Human IgG1 N297A , kappa Isotype Control Cat. No. 756244; Left Plot or BD Horizon BV480 Biosimilar Anti-Human CD20 Obinutuzumab Biosimilar antibody Cat. No. 570971/571042; Right Plot . The erythrocytes were lysed with BD FACS Lysing Solution Cat. No. 349202 . The bivariate pseudocolor density plot showing the correlated expression of CD20 Obinutuzumab Biosimilar or Ig Isotype control staining versus CD19 was derived from gated events with the forward and side light-scatter characteristics of intact lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo Software. Show More Flow cytometric analysis of Human CD20 Obinutuzumab Biosimilar expression on Human peripheral blood leukocytes. Human whole blood was stained with BD OptiBuild BV480 Human IgG1 N297A , kappa Isotype Control Cat. No. 756244; Left Plot or BD Horizon BV480 Biosimilar Anti-Human CD20 Obinutuzumab Biosimilar antibody Cat. No. 570971/571042; Right Plot . The erythrocytes were lysed with BD FACS Lysing Solution Cat. No. 349202 . The bivariate pseudocolor density plot showing the correlated expression of CD20 Obinutuzumab Biosimilar or Ig Isotype control staining versus side light-scatter SSC-A signals was derived from gated events with the forward and side light-scatter characteristics of intact leukocyte populations. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo Software. Flow cytometric analysis of Human CD20 Obinutuzumab Biosimilar expression on Human peripheral blood lymphocytes. Human whole blood was stained with PE Mouse Anti-Human CD19 antibody Cat. No. 555413 and with either BD OptiBuild BV480 Human IgG1 N297A , kappa Isotype Control Cat. No. 756244; Left Plot or BD Horizon BV480 Biosimilar Anti-Human CD20 Obinutuzumab Biosimilar antibody Cat. No. 570971/571042; Right Plot . The erythrocytes were lysed with BD FACS Lysing Solution Cat. No. 349202 . The bivariate pseudocolor density plot showing the correlated expression of CD20 Obinutuzumab Biosimilar or Ig Isotype control staining versus CD19 was derived from gated events with the forward and side light-scatter characteristics of intact lymphocytes. Flow cytometry and data analysis were performed using a BD LSRFortessa X-20 Cell Analyzer System and FlowJo Software.